JEFFREY J. KIMBELL & ASSOCIATES, INC.

View full entity profile (contributions, contracts, SEC) →

Lobbying Income

$61.1M

Filings

2,696

Unique Clients

Active Period

1999–2026

Lobbying Income by Year

Registrant-reported income from clients on LDA filings

Year	Lobbying Income	Filings	Clients
2026	$3,726,250	230	84
2025	$4,525,000	257	70
2024	$5,080,750	210	48
2023	$4,345,250	160	43
2022	$4,431,000	167	44
2021	$4,550,000	168	45
2020	$4,560,000	193	51
2019	$4,157,000	167	45
2018	$3,604,000	148	38
2017	$3,194,000	142	31
2016	$2,084,000	95	26
2015	$2,013,000	93	26
2014	$1,654,100	79	20
2013	$1,003,750	78	22
2012	$1,509,500	100	20
2011	$1,227,000	80	17
2010	$923,000	49	12
2009	$1,864,131	61	15
2008	$1,307,700	60	17
2007	$1,167,700	38	20
2006	$1,363,000	41	20
2005	$836,875	37	17
2004	$274,000	8	5
2003	$440,000	10	5
2002	$360,000	6	4
2001	$140,000	8	5
2000	$660,000	6	3
1999	$120,000	5	3

Top Clients

Largest clients by registrant-reported income

Client	Reported Income	Filings	Period
ASTELLAS PHARMA US	$4,207,500	92	2006–2026
ALLERGAN, INC.	$2,776,981	67	2005–2020
SUMITOMO PHARMA CO., LTD. (FORMERLY SUNOVION PHARMACEUTICALS, INC.)	$2,299,000	59	2011–2024
GILEAD SCIENCES, INC.	$2,130,000	30	2019–2026
U.S. RENAL CARE	$1,980,000	43	2016–2026
BOEHRINGER INGELHEIM PHARMACEUTICALS INC	$1,960,000	51	2015–2026
LIVANOVA USA INC	$1,862,000	76	2009–2026
ACCURAY INCORPORATED	$1,600,000	49	2015–2026
HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.)	$1,510,000	39	2015–2024
BIOGEN INC.	$1,500,000	31	2019–2025
SSI GROUP	$1,232,100	73	2009–2026
BOSTON SCIENTIFIC CORP	$1,215,000	13	1999–2007
BROOKDALE SENIOR LIVING INC.	$1,200,000	31	2019–2026
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION (FKN TENNESSEE FARM BR. ASSN.)	$1,200,000	42	2017–2026
SPARK THERAPEUTICS, INC.	$1,140,000	43	2015–2025
ARDELYX INC	$1,130,000	34	2018–2026
VALEANT PHARMACEUTICALS INC	$668,350	43	2005–2015
ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY	$1,020,000	47	2018–2026
ACELRX PHARMACEUTICALS, INC.	$970,000	21	2017–2022
CATALYST PHARMACEUTICALS	$860,000	30	2019–2026
SEPRACOR	$840,000	6	1999–2002
Eagle Pharmaceuticals, Inc.	$810,000	28	2017–2024
NEVRO CORPORATION	$780,000	28	2018–2025
GLAUKOS CORPORATION (FKA AVEDRO, INC.)	$740,000	40	2015–2026
ABBOTT	$724,000	40	2009–2017

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	2,367
SENATE	2,353
Health & Human Services, Dept of (HHS)	204
Centers For Medicare and Medicaid Services (CMS)	101
Executive Office of the President (EOP)	67
Food & Drug Administration (FDA)	59
Office of Management & Budget (OMB)	28
Centers For Disease Control & Prevention (CDC)	21
U.S. Trade Representative (USTR)	16
Defense, Dept of (DOD)	11
Treasury, Dept of	10
Commerce, Dept of (DOC)	7
Labor, Dept of (DOL)	4
Natl Institutes of Health (NIH)	4
Energy, Dept of	3
Federal Emergency Management Agency (FEMA)	3
Housing & Urban Development, Dept of (HUD)	2
Natl Economic Council (NEC)	2
Securities & Exchange Commission (SEC)	2
UNDETERMINED	2

Top Issues Lobbied

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	2,174
Medicare/Medicaid	Medicare/Medicaid	949
Trade (domestic/foreign)	Trade (domestic/foreign)	56
Defense	Defense	46
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	45
Copyright/Patent/Trademark	Copyright/Patent/Trademark	41
Veterans	Veterans	38
Budget/Appropriations	Budget/Appropriations	32
Housing	Housing	31
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	24
Agriculture	Agriculture	16
Environment/Superfund	Environment/Superfund	13
Manufacturing	Manufacturing	13
Tariff (miscellaneous tariff bills)	Tariff (miscellaneous tariff bills)	11
Pharmacy	Pharmacy	10
Financial Institutions/Investments/Securities	Financial Institutions/Investments/Securities	8
Immigration	Immigration	5
Science/Technology	Science/Technology	5
Animals	Animals	5
Labor Issues/Antitrust/Workplace	Labor Issues/Antitrust/Workplace	4

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 7389117th Congress

MVP Act

2026 · third_quarter · Client: INSTITUTE FOR GENE THERAPIES

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $20,000

Matched citations: H.R. 7389

H.R. 2199119th Congress

Restore Protections for Dialysis Patients Act

2026 · third_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R.2199

H.R. 6214119th Congress

Kidney Care Access Protection Act

2026 · third_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6214

S. 1173119th Congress

Restore Protections for Dialysis Patients Act

2026 · third_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S.1173

Show 21 more cited filings

S. 2730119th Congress

Kidney Care Access Protection Act

2026 · third_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S.2730

H.R. 2527119th Congress

Early Detection of Vision Impairments for Children Act of 2025

2026 · third_quarter · Client: GLAUKOS CORPORATION (FKA AVEDRO, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $20,000

Matched citations: H.R. 2527

H.R. 7389117th Congress

MVP Act

2026 · second_quarter · Client: INSTITUTE FOR GENE THERAPIES

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $20,000

Matched citations: H.R. 7389

H.R. 2199119th Congress

Restore Protections for Dialysis Patients Act

2026 · second_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R.2199

H.R. 6214119th Congress

Kidney Care Access Protection Act

2026 · second_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6214

S. 1173119th Congress

Restore Protections for Dialysis Patients Act

2026 · second_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S.1173

S. 2730119th Congress

Kidney Care Access Protection Act

2026 · second_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S.2730

H.R. 2527119th Congress

Early Detection of Vision Impairments for Children Act of 2025

2026 · second_quarter · Client: GLAUKOS CORPORATION (FKA AVEDRO, INC.)

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $20,000

Matched citations: H.R. 2527

H.R. 7389117th Congress

MVP Act

2026 · first_quarter · Client: INSTITUTE FOR GENE THERAPIES

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $20,000

Matched citations: H.R. 7389

H.R. 2199119th Congress

Restore Protections for Dialysis Patients Act

2026 · first_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R.2199

H.R. 6214119th Congress

Kidney Care Access Protection Act

2026 · first_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6214

S. 1173119th Congress

Restore Protections for Dialysis Patients Act

2026 · first_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S.1173

S. 2730119th Congress

Kidney Care Access Protection Act

2026 · first_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S.2730

H.R. 7389117th Congress

MVP Act

2025 · fourth_quarter · Client: INSTITUTE FOR GENE THERAPIES

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $20,000

Matched citations: H.R. 7389

H.R. 2199119th Congress

Restore Protections for Dialysis Patients Act

2025 · fourth_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R.2199

H.R. 6214119th Congress

Kidney Care Access Protection Act

2025 · fourth_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6214

S. 1173119th Congress

Restore Protections for Dialysis Patients Act

2025 · fourth_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S.1173

S. 2730119th Congress

Kidney Care Access Protection Act

2025 · fourth_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S.2730

H.R. 7389117th Congress

MVP Act

2025 · third_quarter · Client: INSTITUTE FOR GENE THERAPIES

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $20,000

Matched citations: H.R. 7389

H.R. 2199119th Congress

Restore Protections for Dialysis Patients Act

2025 · third_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R.2199

S. 1173119th Congress

Restore Protections for Dialysis Patients Act

2025 · third_quarter · Client: U.S. RENAL CARE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S.1173

Source: Senate LDA

JEFFREY J. KIMBELL & ASSOCIATES, INC. — Lobbying Disclosure | Poliscope